Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Investments: 2016-2024

Historic Long-Term Investments for Seres Therapeutics (MCRB) over the last 7 years, with Mar 2024 value amounting to $1.4 million.

  • Seres Therapeutics' Long-Term Investments changed negligibly% to $1.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.4 million for FY2023, which is negligibly% changed negligibly from last year.
  • Per Seres Therapeutics' latest filing, its Long-Term Investments stood at $1.4 million for Q1 2024, which was down 0.00% from $1.4 million recorded in Q4 2023.
  • In the past 5 years, Seres Therapeutics' Long-Term Investments registered a high of $49.8 million during Q4 2020, and its lowest value of $1.4 million during Q1 2020.
  • Its 3-year average for Long-Term Investments is $1.4 million, with a median of $1.4 million in 2024.
  • As far as peak fluctuations go, Seres Therapeutics' Long-Term Investments spiked by 3,458.93% in 2020, and later tumbled by 97.19% in 2021.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Long-Term Investments stood at $49.8 million in 2020, then tumbled by 97.19% to $1.4 million in 2021, then remained steady at $1.4 million in 2022, then remained steady at $1.4 million in 2023, then remained steady at $1.4 million in 2024.
  • Its Long-Term Investments was $1.4 million in Q1 2024, compared to $1.4 million in Q4 2023 and $1.4 million in Q3 2023.